Cargando…

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

INTRODUCTION: Long-acting injectable antipsychotics (LAIs) have proven to be effective in the maintenance treatment of patients suffering from schizophrenia, and their safety and tolerability profiles represent a key factor in their long-term use and choice in clinical practice. Paliperidone palmita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicala, Giuseppe, de Filippis, Renato, Barbieri, Maria Antonietta, Cutroneo, Paola Maria, De Fazio, Pasquale, Schoretsanitis, Georgios, Spina, Edoardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116827/ https://www.ncbi.nlm.nih.gov/pubmed/37091708 http://dx.doi.org/10.3389/fpsyt.2023.1130636

Ejemplares similares

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2021)

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
por: Li, Kanglai, et al.
Publicado: (2021)

Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
por: Barbieri, Maria Antonietta, et al.
Publicado: (2020)

Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
por: Russu, Alberto, et al.
Publicado: (2018)

Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study
por: Cicala, Giuseppe, et al.
Publicado: (2020)

Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance
por: Ruggiero, Rosanna, et al.
Publicado: (2022)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo
por: Shi, Junfeng, et al.
Publicado: (2022)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
por: Romero Guillena, S.L., et al.
Publicado: (2022)

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
por: Fife, Daniel, et al.
Publicado: (2022)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Paliperidone palmitate-induced enuresis: a case report
por: Cruz, S., et al.
Publicado: (2022)

Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal
por: Marques-Teixeira, João, et al.
Publicado: (2022)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents
por: Spina, Edoardo, et al.
Publicado: (2020)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions and emergency room visits. 66 months of follow-up
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
por: Karslıoǧlu, Ersin Hatice, et al.
Publicado: (2016)

Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
por: Greenberg, William M., et al.
Publicado: (2015)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Paliperidone palmitate-induced facial angioedema: A case report
por: Srifuengfung, Maytinee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u11bvhgn9ds652ia2igsccbkqc